Compare AbCellera Biologics Inc (ABCL) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dropbox Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Dropbox Inc trades at $28.76 (market cap $6.73B). The key difference: Dropbox Inc is far larger — about 2.9× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | DBX | |
|---|---|---|
Market Cap | $2.35B | $6.73B |
Sector | Health | Technology |
52-Week High | $8.12 | $32.17 |
52-Week Low | $2.78 | $22.06 |
Enterprise Value | $1.99B | $9.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
DBX trades at $28.85, up 1.02% today, with a bullish technical signal from moving averages and a consensus price target of $30.00. The company maintains strong profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent developments include a new $900 million stock repurchase program and CEO transition news from Reuters on 2026-05-26.
Outlook remains positive with steady revenue near $2.5 billion and robust cash flow, though risks include high debt levels and competitive pressures. The stock offers moderate upside to the price target with support from buybacks, but investors should monitor execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
